The first evidence-based consensus statement on tumor immunotherapy for the treatment ofpatients with bladder cancer was developed by the Society for Immunotherapy of Cancer (SITC) and published online by the Journal for ImmunoTherapy of Cancer, in 2017.Immunotherapeutic drugs approved for the treatment of bladder cancer include several checkpoint inhibitors and the immunotherapeutic vaccine, Bacillus Calmette-Guérin (BCG). This consensus statement provides expert evidence-based recommendations for the use of these immunotherapies, including recommendations for patient selection, toxicity management, clinical end points and sequencing or combination of therapies.SITC Cancer Immunotherapy Guidelines (CIGs) are a collection of clinical practice guidelines developed by multi-disciplinary panels of experts who draw from their own practical experience as well as evidence in the published literature and clinical trial data to develop evidence- and consensus-based recommendations. SITC uses as a model the Institute of Medicine's 2011 "Standards for Developing Trustworthy Clinical Practice Guidelines" to ensure the recommendations are unbiased, transparent and balanced and will aid oncologists in effective clinical decision-making concerning patient selection, toxicity management, response evaluation, and the sequencing or combination of therapies, among other topics.
Published Aug. 15, 2017 in the Journal for ImmunoTherapy of Cancer (JITC) as "The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma."
Key points from SITC's Cancer Immunotherapy Guidelines Bladder Carcinoma have been distilled into a Pocket Guide. This condensed, easily accessible version of the full Cancer Immunotherapy Guideline is a quick-reference tool available in both digital and print.Download SITC's Cancer Immunotherapy Guidelines Bladder Carcinoma Pocket Guide on any desktop or mobile device today.*
*Available only through the Guideline Central App.
ORDER Digital/Print Guide
Arjun V. Balar, MD — Perlmutter Cancer Center - New York University Langone Medical Center
Peter Black, MD, FACS, FRCSC — University of British Columbia
Matthew T. Campbell, MD, MS — The University of Texas MD Anderson Cancer Center
Gail S. Dykstra, Patient Advocate — Dykstra Research
Petros Grivas, MD, PhD — University of Washington
Shilpa Gupta, MD — Cleveland Clinic Taussig Cancer Institute
Christopher J. Hoimes, MD — Duke Cancer Institute
Lidia P. Lopez, APN-C — The University of Texas MD Anderson Cancer Center
Joshua J. Meeks, MD, PhD — Northwestern Medicine Feinberg School of Medicine
Elizabeth R. Plimack, MD, MS — Fox Chase Cancer Center
Jonathan E. Rosenberg, MD — Memorial Sloan Kettering Cancer Center
Neil Shore, MD, FACS — Carolina Urologic Research Center
Gary D. Steinberg, MD — Perlmutter Cancer Center - New York University Langonge Medical Center
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: email@example.com